Publications by authors named "Monika Caban"
Article Synopsis
- Small-molecule EGFR inhibitors have improved survival rates in EGFR-mutated lung cancer, but they often cause severe side effects and resistance.
- A new prodrug, KP2334, selectively activates in tumor areas with low oxygen levels, releasing a novel EGFR inhibitor, KP2187, designed to work effectively in those regions.
- Research shows that KP2187 has similar binding and inhibitory effects on EGFR as established drugs like erlotinib and gefitinib, and it also works well in combination with VEGFR inhibitors, suggesting it could reduce toxicity in combination therapies.
In recent years, Candida albicans infections treatment has become a growing problem because, among others, pathogenic strains are capable to develop resistance to the administered drugs. The elaboration of rapid and accurate method of resistance assessment is an important goal of many studies. They aim to avoid inappropriate dosage or drug choice, which may be life threatening in case of severe candidiasis.
View Article and Find Full Text PDF